9% Increase Year-on-Year
Net Loss Due to One-Time Expenses
Topline Results to Be Announced in the Second Half

On July 29, HanAll Biopharma announced that its consolidated sales for the second quarter reached 44.3 billion won, with operating profit at 5.6 billion won. These figures represent increases of 9% and 389%, respectively, compared to the same period last year.


The pharmaceutical business in the second quarter maintained strong results, driven by the balanced growth of its major products. The probiotic drug "Biotop" and the non-absorbable antibiotic "Normix" both exceeded cumulative sales of 14.8 billion won and 10 billion won, respectively, during the first half of the year. The prostate cancer and central precocious puberty treatment "Eligard" also continued to see stable growth in prescriptions.

HanAll Biopharma Reports Q2 Sales of 44.3 Billion Won... "Balanced Growth of Key Products" View original image

Operating profit came in at 5.6 billion won, as previously deferred revenue was recognized after the completion of the global Phase 3 trial for Batoclimab in thyroid eye disease (TED). On the other hand, net loss amounted to 19.2 billion won, due to a one-time increase in expenses such as impairment losses related to development projects.


In the research and development (R&D) segment, the company’s next-generation autoimmune disease treatment, IMERO-PLUVAT, demonstrated efficacy in actual patients for the first time through interim results from its registration clinical trial in difficult-to-treat rheumatoid arthritis (D2T RA).


In the second half of the year, topline results are scheduled to be announced for the registration clinical study of IMERO-PLUVAT in difficult-to-treat rheumatoid arthritis and for the Phase 2 clinical trial in cutaneous lupus erythematosus (CLE).



A HanAll Biopharma official stated, "We are maintaining a solid business foundation based on stable growth of our key pharmaceuticals and research and development achievements," and added, "Through the clinical results scheduled in the second half, we expect to validate the value of IMERO-PLUVAT in earnest."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing